Merck presents one-year BRUNELLO results at AAO 2026
Merck presented one-year results from its pivotal Phase 2b/3 BRUNELLO study evaluating remigromig, a tri-specific agonist targeting the Wnt pathway, in adults with diabetic macular edema at AAO 2026.